KR20020075805A - 5-알킬피리도[2,3-ｄ]피리미딘 타이로신 카이나제 억제제 - Google Patents

5-알킬피리도[2,3-ｄ]피리미딘 타이로신 카이나제 억제제 Download PDF

Info

Publication number
KR20020075805A
KR20020075805A KR1020027011627A KR20027011627A KR20020075805A KR 20020075805 A KR20020075805 A KR 20020075805A KR 1020027011627 A KR1020027011627 A KR 1020027011627A KR 20027011627 A KR20027011627 A KR 20027011627A KR 20020075805 A KR20020075805 A KR 20020075805A
Authority
KR
South Korea
Prior art keywords
compound
methyl
pyrido
cyclopentyl
pyrimidin
Prior art date
Application number
KR1020027011627A
Other languages
English (en)
Korean (ko)
Inventor
리차드 존 부트
엘렌 마이라 도브루신
피터 로렌스 투굿
스코트 노만 반데어웰
Original Assignee
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워너-램버트 캄파니 filed Critical 워너-램버트 캄파니
Publication of KR20020075805A publication Critical patent/KR20020075805A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020027011627A 2000-03-06 2001-01-29 5-알킬피리도[2,3-ｄ]피리미딘 타이로신 카이나제 억제제 KR20020075805A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
US60/187,124 2000-03-06
PCT/US2001/002657 WO2001070741A1 (fr) 2000-03-06 2001-01-29 Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido[2,3-d]pyrimidines

Publications (1)

Publication Number Publication Date
KR20020075805A true KR20020075805A (ko) 2002-10-05

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027011627A KR20020075805A (ko) 2000-03-06 2001-01-29 5-알킬피리도[2,3-ｄ]피리미딘 타이로신 카이나제 억제제

Country Status (36)

Country Link
EP (1) EP1268476A1 (fr)
JP (1) JP2003528101A (fr)
KR (1) KR20020075805A (fr)
CN (1) CN1422268A (fr)
AP (1) AP2002002643A0 (fr)
AR (1) AR034119A1 (fr)
AU (1) AU2001233028A1 (fr)
BG (1) BG107161A (fr)
BR (1) BR0109056A (fr)
CA (1) CA2401368A1 (fr)
CO (1) CO5280200A1 (fr)
CR (1) CR6736A (fr)
CZ (1) CZ20022929A3 (fr)
DZ (1) DZ3308A1 (fr)
EA (1) EA200200802A1 (fr)
EE (1) EE200200506A (fr)
GT (1) GT200100037A (fr)
HN (1) HN2001000040A (fr)
HR (1) HRP20020798A2 (fr)
HU (1) HUP0300136A2 (fr)
IL (1) IL151480A0 (fr)
IS (1) IS6524A (fr)
MA (1) MA26881A1 (fr)
MX (1) MXPA02008535A (fr)
NO (1) NO20024235L (fr)
NZ (1) NZ520962A (fr)
OA (1) OA12227A (fr)
PA (1) PA8513201A1 (fr)
PE (1) PE20011177A1 (fr)
PL (1) PL358271A1 (fr)
SK (1) SK12472002A3 (fr)
SV (1) SV2001000338A (fr)
TN (1) TNSN01036A1 (fr)
WO (1) WO2001070741A1 (fr)
YU (1) YU66502A (fr)
ZA (1) ZA200207110B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140058438A (ko) * 2011-05-17 2014-05-14 프린시피아 바이오파마, 인코퍼레이티드 타이로신 키나아제 저해제
KR20190012231A (ko) * 2016-06-01 2019-02-08 엑스커버리 홀딩스, 인코포레이티드 단백질 키나제 활성을 억제하는 화합물의 결정 형태 및 이의 응용

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA03003612A (es) 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
ATE305303T1 (de) * 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
JP4166991B2 (ja) 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
SI1470124T1 (sl) 2002-01-22 2006-04-30 Warner Lambert Co 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
AU2003225072A1 (en) 2002-04-19 2003-11-03 Smithkline Beecham Corporation Novel compounds
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CA2536954C (fr) 2003-08-29 2012-11-27 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
EP1685131B1 (fr) 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Pyrido-7-pyrimidin-7-ones substitues hydroxyalkyle
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (fr) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
CA2575804A1 (fr) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones utilisees en tant qu'inhibiteurs des plk (polo-like-kinases)
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
JP2008527007A (ja) 2005-01-14 2008-07-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ｒａｆ−キナーゼ阻害活性を有するシンナミドおよびヒドロシンナミド誘導体
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
TWI389690B (zh) 2005-03-25 2013-03-21 Glaxo Group Ltd 新穎化合物（一）
KR20080002865A (ko) 2005-03-25 2008-01-04 글락소 그룹 리미티드 피리도[２,３-ｄ]피리미딘-７-온 및３,４-디히드로피리미도[４,５-ｄ]피리미딘-２(１ｈ)-온유도체의 제조 방법
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
EA016945B1 (ru) * 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
SI2074122T1 (sl) 2006-09-15 2011-10-28 Pfizer Prod Inc Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3
JP2010506902A (ja) * 2006-10-16 2010-03-04 ジーピーシー・バイオテック・インコーポレーテッド ピリド［２，３−ｄ］ピリミジン類およびキナーゼ阻害剤としてのそれらの使用
EP1914234A1 (fr) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
WO2008055013A2 (fr) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de la kinase c-fms
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AU2008237507B2 (en) * 2007-04-03 2014-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
AU2008262837B2 (en) * 2007-06-15 2013-05-23 Msd K.K. Bicycloaniline derivative
EP2185559A1 (fr) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Forme cristalline d'un dérivé de dihydroptéridione
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
WO2009079797A1 (fr) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Composés et procédé pour le traitement du cancer
EP2100894A1 (fr) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
MX2010010975A (es) 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
CA2999321A1 (fr) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Composes inhibiteurs et procedes de traitement du cance
PA8843901A1 (es) 2008-09-30 2010-05-26 INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP2013507395A (ja) * 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
US8889696B2 (en) 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
WO2011100319A1 (fr) 2010-02-09 2011-08-18 Exelixis, Inc. Procédés de traitement du cancer à l'aide d'inhibiteurs pyridopyrimidinone de pi3k et mtor en combinaison avec des inhibiteurs d'autophagie
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US8987267B2 (en) 2010-08-05 2015-03-24 Temple University—Of the Commonwealth System of Higher Education 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
JP6000273B2 (ja) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー 大環状キナーゼ阻害剤
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
SI2958916T1 (sl) * 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
EP3024464A1 (fr) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Traitement du syndrome myélodysplasique
CA2954189A1 (fr) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido [2,3-d] pyrimidin -7 (8h)-one utilises en tant qu'inhibiteurs de cdk et utilisations de ceux-ci
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TN2019000039A1 (en) 2016-08-15 2020-07-15 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
WO2018160076A1 (fr) * 2017-03-03 2018-09-07 Auckland Uniservices Limited Inhibiteurs de kinase fgfr et utilisations pharmaceutiques
EP3752491A4 (fr) 2018-02-15 2021-12-01 Nuvation Bio Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
TW202035406A (zh) * 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 作為cdk-hdac雙通路抑制劑的雜環化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
WO2022188755A1 (fr) * 2021-03-08 2022-09-15 暨南大学 Composé à base de pyridopyrimidine et son utilisation
WO2024056091A1 (fr) * 2022-09-16 2024-03-21 华东师范大学 Dérivé de pyridonopyrimidine en tant qu'inhibiteur de rsk et son utilisation
WO2024099403A1 (fr) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Composé thioéther ayant une propriété de médicament doux et son utilisation, composition pharmaceutique et utilisation associées
WO2024107730A1 (fr) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Méthodes et compositions pour le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
JP2001509805A (ja) * 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
NZ508268A (en) * 1998-05-26 2004-02-27 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140058438A (ko) * 2011-05-17 2014-05-14 프린시피아 바이오파마, 인코퍼레이티드 타이로신 키나아제 저해제
KR20190012231A (ko) * 2016-06-01 2019-02-08 엑스커버리 홀딩스, 인코포레이티드 단백질 키나제 활성을 억제하는 화합물의 결정 형태 및 이의 응용

Also Published As

Publication number Publication date
EE200200506A (et) 2004-02-16
IS6524A (is) 2002-08-23
CZ20022929A3 (cs) 2003-02-12
SK12472002A3 (sk) 2003-04-01
BG107161A (en) 2003-06-30
GT200100037A (es) 2002-03-04
MXPA02008535A (es) 2002-12-13
DZ3308A1 (fr) 2001-09-27
NO20024235L (no) 2002-11-05
TNSN01036A1 (en) 2005-11-10
AU2001233028A1 (en) 2001-10-03
EA200200802A1 (ru) 2003-02-27
OA12227A (en) 2004-03-18
ZA200207110B (en) 2003-12-04
HRP20020798A2 (en) 2004-02-29
CN1422268A (zh) 2003-06-04
SV2001000338A (es) 2001-11-30
HN2001000040A (es) 2001-09-06
PA8513201A1 (es) 2003-06-30
YU66502A (sh) 2005-09-19
BR0109056A (pt) 2003-06-03
IL151480A0 (en) 2003-04-10
CR6736A (es) 2004-03-10
JP2003528101A (ja) 2003-09-24
HUP0300136A2 (en) 2003-05-28
NO20024235D0 (no) 2002-09-05
PE20011177A1 (es) 2001-11-23
CO5280200A1 (es) 2003-05-30
MA26881A1 (fr) 2004-12-20
AP2002002643A0 (en) 2002-12-31
PL358271A1 (en) 2004-08-09
EP1268476A1 (fr) 2003-01-02
WO2001070741A1 (fr) 2001-09-27
CA2401368A1 (fr) 2001-09-27
AR034119A1 (es) 2004-02-04
NZ520962A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
KR20020075805A (ko) 5-알킬피리도[2,3-ｄ]피리미딘 타이로신 카이나제 억제제
US7208489B2 (en) 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
JP5513558B2 (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
RU2326882C2 (ru) Пиримидиновые соединения, обладающие антипролиферативной активностью (ii)
US7371750B2 (en) Compounds and compositions as protein kinase inhibitors
JP4758349B2 (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
US7053070B2 (en) Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
KR20020065939A (ko) 피리도[2,3-ｄ]피리미딘-2,7-디아민 카이나제 억제제
CN101616895A (zh) 作为蛋白激酶抑制剂的化合物和组合物
SK3542002A3 (en) Pteridinones as kinase inhibitors
UA74850C2 (en) Amide derivatives as nmda receptor antagonists
KR20090073120A (ko) 피라졸로[1,5-ａ]피리미딘 유도체 및 이들의 치료 용도
CN100439365C (zh) 用作蛋白激酶抑制剂的化合物和组合物
TWI464170B (zh) ５-酮基-５，８-二氫吡啶并［２，３-ｄ］嘧啶衍生物，其製備及其治療用途
US20090030020A1 (en) 7H-Pyrido[3,4-D]Pyrimidin-8-Ones, Their Manufacture and Use as Protein Kinase Inhibitors
SK2582002A3 (en) Fused pyrrolecarboxamides as GABA brain receptor ligands
KR20010102544A (ko) 카르바모일 테트라히드로피리딘 유도체
CN101479263A (zh) 药用化合物

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid